{"entity":{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","aka":["TNBC trials recruiting","Open TNBC trials"],"tldr":"Every phase 2 or 3 drug trial that was recruiting, about to open or still running for triple-negative breast cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.","summary":"The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 2/3 and 3 studies naming triple-negative breast cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment: 395 studies, of which 92 were already in the corpus and 18 are hand-written here. The 213 new registry-only records linked here carry the registry facts (title, sponsor, enrolment, dates, interventions, conditions, the triple-negative eligibility sentence and the countries) and no outcomes; trials with a HER2-positive or hormone-receptor-positive cohort alongside a triple-negative one are left out. Of the 213, 146 are phase 2, 32 phase 1/2, 31 phase 3 and 4 phase 2/3; 125 are recruiting, 75 not yet recruiting, 3 enrolling by invitation and 10 phase 3 or 2/3 trials active but closed. Most are run from China, the United States, France and Italy; the United Kingdom appears as a site in the hand-written UK trials (PARTNER at 30 hospitals, PHOENIX at 6, c-TRAK TN at 17, DIAMOND and BARBICAN at Barts, A-BRAVE at 8) and in the industry phase 3 trials ASCENT-03, ASCENT-04, ASCENT-05, TROPION-Breast02, 03, 04 and 05, CAPItello-290 and BEGONIA, whose UK sites are quoted on each record. The ISRCTN registry lists 41 hits for the same search, almost all dual-registered on ClinicalTrials.gov (DIAMOND is one), plus observational and imaging studies not carried here.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov search: triple negative breast cancer, interventional, phase 2 and 3, recruiting","url":"https://clinicaltrials.gov/search?cond=triple%20negative%20breast%20cancer&aggFilters=phase:2%203,status:rec%20not%20act,studyType:int"},{"label":"ISRCTN registry search: triple negative breast","url":"https://www.isrctn.com/search?q=triple+negative+breast"}],"tags":[],"related":[],"cancers":["tnbc","tnbc-early","tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["de-escalation","rcb","pcr","cps"],"trials":["partner","phoenix","c-trak-tn","diamond","barbican","a-brave","ascent-03","ascent-04","ascent-05","tropion-breast02","tropion-breast03","tropion-breast05","nct06112379","nct03997123","nct03742102","optimice-pcr","scarlet-s2212","swog-s1418","nct02641847","nct01057069","nct03168880","nct02488967","nct02455141","nct05552001","nct04335669","nct04595565","nct05078047","nct04296175","nct06910072","nct07359404","nct07376629","nct05821686","nct07107217","nct06977542","nct07413601","nct07681297","nct04301739","nct07721259","nct07788222","nct07021261","nct07743723","nct07011823","nct07407517","nct07299409","nct07487519","nct07486687","nct07372079","nct06731153","nct07441512","nct07743632","nct07458204","nct05862610","nct07752550","nct05522491","nct06404736","nct07509515","nct07015853","nct07151586","nct06371807","nct07552181","nct07762703","nct07292142","nct07244874","nct02802423","nct06202313","nct07040644","nct06724263","nct06632405","nct06849492","nct07054242","nct06746870","nct05128734","nct07256964","nct07628504","nct07101614","nct07103447","nct06819319","nct07161791","nct07581314","nct06691594","nct07271992","nct07153965","nct07255612","nct07730125","nct06140576","nct06229067","nct06787339","nct07005583","nct07723469","nct05067530","nct06795503","nct06586866","nct07786428","nct07419880","nct07610525","nct07729956","nct05806385","nct07528768","nct06268327","nct07007780","nct07139470","nct07458113","nct07556848","nct06407310","nct07178730","nct07698106","nct06176261","nct04468061","nct06627712","nct05447702","nct07064018","nct07378306","nct07601178","nct06793332","nct06245889","nct04768426","nct06793553","nct06963905","nct06682195","nct04683679","nct06353997","nct04230109","nct06134375","nct06616987","nct06385990","nct06367088","nct06831955","nct07371208","nct06817525","nct07342283","nct06878625","nct06636981","nct07739485","nct05550415","nct06078384","nct05866432","nct06851299","nct05570253","nct07078604","nct04722978","nct04437160","nct05806060","nct05660083","nct06358573","nct07276880","nct06081244","nct07394387","nct07045311","nct07768436","nct05475678","nct06976944","nct04481763","nct05999149","nct07743190","nct05035745","nct04159818","nct05192798","nct06313463","nct06538896","nct05749588","nct07321015","nct06786026","nct06238921","nct04677816","nct07069595","nct06532812","nct06387628","nct05528133","nct07401537","nct05296564","nct06845319","nct03606967","nct04138719","nct06678048","nct05491226","nct05582538","nct06840821","nct07623577","nct06690840","nct06125080","nct05485766","nct07340541","nct06365788","nct07017673","nct07638852","nct04333706","nct06165900","nct06508216","nct06225284","nct06889688","nct05019690","nct04137653","nct06380816","nct05973864","nct05862064","nct06492759","nct05846789","nct06889610","nct06318897","nct06534762","nct05909332","nct06771609","nct06434064","nct06606730","nct05770531","nct06291064","nct07351487","nct06401005","nct07016399","nct07457359","nct06735131","nct06992336","nct07011654","nct06533384","nct05760378","nct07074106","nct04434040","nct04501523","nct03808337","nct07283692","nct06342037","nct07188246","nct06802757","nct05451784","nct05491083","nct07104266","nct05269381","nct04159142","nct04947189","nct06635980","nct04771871"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/tnbc-trials-open-today/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"term":[{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/"},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/"}],"trial":[{"id":"nct07078604","kind":"trial","name":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07078604/"},{"id":"nct04333706","kind":"trial","name":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of S","route":"/trials/nct04333706/"},{"id":"nct05862064","kind":"trial","name":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem","route":"/trials/nct05862064/"},{"id":"nct06724263","kind":"trial","name":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","route":"/trials/nct06724263/"},{"id":"nct06878625","kind":"trial","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","route":"/trials/nct06878625/"},{"id":"nct06380816","kind":"trial","name":"A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer","route":"/trials/nct06380816/"},{"id":"nct06889610","kind":"trial","name":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","route":"/trials/nct06889610/"},{"id":"nct06746870","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Tr","route":"/trials/nct06746870/"},{"id":"nct07743190","kind":"trial","name":"A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P","route":"/trials/nct07743190/"},{"id":"nct07441512","kind":"trial","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","route":"/trials/nct07441512/"},{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/"},{"id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","route":"/trials/nct04501523/"},{"id":"nct07054242","kind":"trial","name":"A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca","route":"/trials/nct07054242/"},{"id":"nct03168880","kind":"trial","name":"A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced","route":"/trials/nct03168880/"},{"id":"nct07101614","kind":"trial","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","route":"/trials/nct07101614/"},{"id":"nct07321015","kind":"trial","name":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","route":"/trials/nct07321015/"},{"id":"nct07556848","kind":"trial","name":"A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07556848/"},{"id":"nct07729956","kind":"trial","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","route":"/trials/nct07729956/"},{"id":"nct05999149","kind":"trial","name":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC","route":"/trials/nct05999149/"},{"id":"nct07768436","kind":"trial","name":"A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer","route":"/trials/nct07768436/"},{"id":"nct07376629","kind":"trial","name":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct07376629/"},{"id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","route":"/trials/nct07743723/"},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/"},{"id":"nct04683679","kind":"trial","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","route":"/trials/nct04683679/"},{"id":"nct07040644","kind":"trial","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","route":"/trials/nct07040644/"},{"id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","route":"/trials/nct05570253/"},{"id":"nct06134375","kind":"trial","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","route":"/trials/nct06134375/"},{"id":"nct04481763","kind":"trial","name":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","route":"/trials/nct04481763/"},{"id":"nct06508216","kind":"trial","name":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat","route":"/trials/nct06508216/"},{"id":"nct06632405","kind":"trial","name":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","route":"/trials/nct06632405/"},{"id":"nct07721259","kind":"trial","name":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","route":"/trials/nct07721259/"},{"id":"a-brave","kind":"trial","name":"A-BRAVE","route":"/trials/a-brave/"},{"id":"nct06268327","kind":"trial","name":"Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy","route":"/trials/nct06268327/"},{"id":"nct04437160","kind":"trial","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","route":"/trials/nct04437160/"},{"id":"nct07407517","kind":"trial","name":"Adjuvant Intensification for LAR","route":"/trials/nct07407517/"},{"id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","route":"/trials/nct02455141/"},{"id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","route":"/trials/nct05192798/"},{"id":"nct06636981","kind":"trial","name":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi","route":"/trials/nct06636981/"},{"id":"nct05660083","kind":"trial","name":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","route":"/trials/nct05660083/"},{"id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","route":"/trials/nct05296564/"},{"id":"nct05019690","kind":"trial","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","route":"/trials/nct05019690/"},{"id":"nct06678048","kind":"trial","name":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","route":"/trials/nct06678048/"},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/"},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/"},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/"},{"id":"nct07015853","kind":"trial","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","route":"/trials/nct07015853/"},{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","route":"/trials/nct04434040/"},{"id":"nct06690840","kind":"trial","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","route":"/trials/nct06690840/"},{"id":"barbican","kind":"trial","name":"BARBICAN","route":"/trials/barbican/"},{"id":"nct06365788","kind":"trial","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","route":"/trials/nct06365788/"},{"id":"nct07610525","kind":"trial","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","route":"/trials/nct07610525/"},{"id":"nct07255612","kind":"trial","name":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","route":"/trials/nct07255612/"},{"id":"nct06793332","kind":"trial","name":"BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","route":"/trials/nct06793332/"},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/"},{"id":"nct06367088","kind":"trial","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","route":"/trials/nct06367088/"},{"id":"nct07107217","kind":"trial","name":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","route":"/trials/nct07107217/"},{"id":"nct07161791","kind":"trial","name":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","route":"/trials/nct07161791/"},{"id":"nct06787339","kind":"trial","name":"Capecitabine in Low Risk Triple Negative Breast Cancer","route":"/trials/nct06787339/"},{"id":"nct05973864","kind":"trial","name":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","route":"/trials/nct05973864/"},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/"},{"id":"nct04296175","kind":"trial","name":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","route":"/trials/nct04296175/"},{"id":"nct06992336","kind":"trial","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","route":"/trials/nct06992336/"},{"id":"nct05770531","kind":"trial","name":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","route":"/trials/nct05770531/"},{"id":"nct05475678","kind":"trial","name":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","route":"/trials/nct05475678/"},{"id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/"},{"id":"nct07762703","kind":"trial","name":"Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl","route":"/trials/nct07762703/"},{"id":"nct07021261","kind":"trial","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","route":"/trials/nct07021261/"},{"id":"nct05067530","kind":"trial","name":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","route":"/trials/nct05067530/"},{"id":"nct06176261","kind":"trial","name":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","route":"/trials/nct06176261/"},{"id":"diamond","kind":"trial","name":"DIAMOND","route":"/trials/diamond/"},{"id":"nct02488967","kind":"trial","name":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","route":"/trials/nct02488967/"},{"id":"nct07401537","kind":"trial","name":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","route":"/trials/nct07401537/"},{"id":"nct06229067","kind":"trial","name":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","route":"/trials/nct06229067/"},{"id":"nct05821686","kind":"trial","name":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","route":"/trials/nct05821686/"},{"id":"nct07698106","kind":"trial","name":"Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","route":"/trials/nct07698106/"},{"id":"nct06840821","kind":"trial","name":"Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor","route":"/trials/nct06840821/"},{"id":"nct07340541","kind":"trial","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","route":"/trials/nct07340541/"},{"id":"nct05760378","kind":"trial","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","route":"/trials/nct05760378/"},{"id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","route":"/trials/nct07299409/"},{"id":"nct07378306","kind":"trial","name":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","route":"/trials/nct07378306/"},{"id":"nct07292142","kind":"trial","name":"FMT in Triple Negative Breast Cancer Guided by ctDNA","route":"/trials/nct07292142/"},{"id":"nct05749588","kind":"trial","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","route":"/trials/nct05749588/"},{"id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","route":"/trials/nct07730125/"},{"id":"nct05528133","kind":"trial","name":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","route":"/trials/nct05528133/"},{"id":"nct05806385","kind":"trial","name":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers","route":"/trials/nct05806385/"},{"id":"nct07528768","kind":"trial","name":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.","route":"/trials/nct07528768/"},{"id":"nct06492759","kind":"trial","name":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","route":"/trials/nct06492759/"},{"id":"nct06849492","kind":"trial","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","route":"/trials/nct06849492/"},{"id":"nct06635980","kind":"trial","name":"Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer","route":"/trials/nct06635980/"},{"id":"nct04159818","kind":"trial","name":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","route":"/trials/nct04159818/"},{"id":"nct07011823","kind":"trial","name":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","route":"/trials/nct07011823/"},{"id":"nct04677816","kind":"trial","name":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","route":"/trials/nct04677816/"},{"id":"nct06793553","kind":"trial","name":"Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC","route":"/trials/nct06793553/"},{"id":"nct06358573","kind":"trial","name":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","route":"/trials/nct06358573/"},{"id":"nct03808337","kind":"trial","name":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina","route":"/trials/nct03808337/"},{"id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","route":"/trials/nct06731153/"},{"id":"nct06586866","kind":"trial","name":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","route":"/trials/nct06586866/"},{"id":"nct07045311","kind":"trial","name":"JS207 Combination Therapy in Triple-negative Breast Cancer","route":"/trials/nct07045311/"},{"id":"nct06831955","kind":"trial","name":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","route":"/trials/nct06831955/"},{"id":"nct06387628","kind":"trial","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","route":"/trials/nct06387628/"},{"id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","route":"/trials/nct04771871/"},{"id":"nct06534762","kind":"trial","name":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","route":"/trials/nct06534762/"},{"id":"nct07371208","kind":"trial","name":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","route":"/trials/nct07371208/"},{"id":"nct06817525","kind":"trial","name":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","route":"/trials/nct06817525/"},{"id":"nct04159142","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","route":"/trials/nct04159142/"},{"id":"nct04138719","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","route":"/trials/nct04138719/"},{"id":"nct01057069","kind":"trial","name":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","route":"/trials/nct01057069/"},{"id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","route":"/trials/nct06081244/"},{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/"},{"id":"nct07351487","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","route":"/trials/nct07351487/"},{"id":"nct06682195","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","route":"/trials/nct06682195/"},{"id":"nct06225284","kind":"trial","name":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","route":"/trials/nct06225284/"},{"id":"nct07016399","kind":"trial","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","route":"/trials/nct07016399/"},{"id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","route":"/trials/nct06353997/"},{"id":"nct06407310","kind":"trial","name":"Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer","route":"/trials/nct06407310/"},{"id":"nct07283692","kind":"trial","name":"Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","route":"/trials/nct07283692/"},{"id":"nct07394387","kind":"trial","name":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","route":"/trials/nct07394387/"},{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","route":"/trials/nct07178730/"},{"id":"nct07372079","kind":"trial","name":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth","route":"/trials/nct07372079/"},{"id":"nct06977542","kind":"trial","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","route":"/trials/nct06977542/"},{"id":"nct07457359","kind":"trial","name":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","route":"/trials/nct07457359/"},{"id":"nct06691594","kind":"trial","name":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","route":"/trials/nct06691594/"},{"id":"nct07188246","kind":"trial","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","route":"/trials/nct07188246/"},{"id":"nct06845319","kind":"trial","name":"NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients","route":"/trials/nct06845319/"},{"id":"nct06795503","kind":"trial","name":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","route":"/trials/nct06795503/"},{"id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","route":"/trials/nct04335669/"},{"id":"nct06342037","kind":"trial","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","route":"/trials/nct06342037/"},{"id":"nct05485766","kind":"trial","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","route":"/trials/nct05485766/"},{"id":"nct05522491","kind":"trial","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","route":"/trials/nct05522491/"},{"id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","route":"/trials/nct06318897/"},{"id":"optimice-pcr","kind":"trial","name":"OptimICE-pCR (A012103)","route":"/trials/optimice-pcr/"},{"id":"nct07581314","kind":"trial","name":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07581314/"},{"id":"nct07739485","kind":"trial","name":"Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study","route":"/trials/nct07739485/"},{"id":"nct06910072","kind":"trial","name":"Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN","route":"/trials/nct06910072/"},{"id":"nct06533384","kind":"trial","name":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","route":"/trials/nct06533384/"},{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/"},{"id":"nct06976944","kind":"trial","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","route":"/trials/nct06976944/"},{"id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","route":"/trials/nct07486687/"},{"id":"nct05491083","kind":"trial","name":"Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer","route":"/trials/nct05491083/"},{"id":"nct06078384","kind":"trial","name":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","route":"/trials/nct06078384/"},{"id":"nct07458204","kind":"trial","name":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","route":"/trials/nct07458204/"},{"id":"nct05269381","kind":"trial","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","route":"/trials/nct05269381/"},{"id":"nct06606730","kind":"trial","name":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","route":"/trials/nct06606730/"},{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/"},{"id":"nct07413601","kind":"trial","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","route":"/trials/nct07413601/"},{"id":"nct07723469","kind":"trial","name":"Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery","route":"/trials/nct07723469/"},{"id":"nct02802423","kind":"trial","name":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","route":"/trials/nct02802423/"},{"id":"nct06771609","kind":"trial","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","route":"/trials/nct06771609/"},{"id":"nct05866432","kind":"trial","name":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","route":"/trials/nct05866432/"},{"id":"nct07487519","kind":"trial","name":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br","route":"/trials/nct07487519/"},{"id":"nct07017673","kind":"trial","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","route":"/trials/nct07017673/"},{"id":"nct07552181","kind":"trial","name":"Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer","route":"/trials/nct07552181/"},{"id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/"},{"id":"phoenix","kind":"trial","name":"PHOENIX DDR/Anti-PD-L1","route":"/trials/phoenix/"},{"id":"nct06802757","kind":"trial","name":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","route":"/trials/nct06802757/"},{"id":"nct05806060","kind":"trial","name":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05806060/"},{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","route":"/trials/nct07069595/"},{"id":"nct07276880","kind":"trial","name":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","route":"/trials/nct07276880/"},{"id":"nct06616987","kind":"trial","name":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06616987/"},{"id":"nct07103447","kind":"trial","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","route":"/trials/nct07103447/"},{"id":"nct06786026","kind":"trial","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","route":"/trials/nct06786026/"},{"id":"nct06404736","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer","route":"/trials/nct06404736/"},{"id":"nct07342283","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","route":"/trials/nct07342283/"},{"id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","route":"/trials/nct07509515/"},{"id":"nct07601178","kind":"trial","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","route":"/trials/nct07601178/"},{"id":"nct07419880","kind":"trial","name":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","route":"/trials/nct07419880/"},{"id":"nct05491226","kind":"trial","name":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","route":"/trials/nct05491226/"},{"id":"nct05582538","kind":"trial","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","route":"/trials/nct05582538/"},{"id":"nct07752550","kind":"trial","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","route":"/trials/nct07752550/"},{"id":"nct07623577","kind":"trial","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","route":"/trials/nct07623577/"},{"id":"nct07244874","kind":"trial","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","route":"/trials/nct07244874/"},{"id":"nct07458113","kind":"trial","name":"Sac-TMT for Active TNBC Brain Metastases","route":"/trials/nct07458113/"},{"id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","route":"/trials/nct07628504/"},{"id":"nct06963905","kind":"trial","name":"Saci Nivo Rela for TNBC","route":"/trials/nct06963905/"},{"id":"nct04468061","kind":"trial","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","route":"/trials/nct04468061/"},{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","route":"/trials/nct07788222/"},{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","route":"/trials/nct06238921/"},{"id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","route":"/trials/nct04595565/"},{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","route":"/trials/nct04230109/"},{"id":"nct07359404","kind":"trial","name":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","route":"/trials/nct07359404/"},{"id":"nct07007780","kind":"trial","name":"Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC","route":"/trials/nct07007780/"},{"id":"nct07139470","kind":"trial","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","route":"/trials/nct07139470/"},{"id":"nct07153965","kind":"trial","name":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07153965/"},{"id":"nct05552001","kind":"trial","name":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","route":"/trials/nct05552001/"},{"id":"nct06627712","kind":"trial","name":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","route":"/trials/nct06627712/"},{"id":"nct06401005","kind":"trial","name":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","route":"/trials/nct06401005/"},{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/"},{"id":"nct05035745","kind":"trial","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","route":"/trials/nct05035745/"},{"id":"nct04768426","kind":"trial","name":"Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer","route":"/trials/nct04768426/"},{"id":"nct04947189","kind":"trial","name":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","route":"/trials/nct04947189/"},{"id":"nct06819319","kind":"trial","name":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","route":"/trials/nct06819319/"},{"id":"nct04722978","kind":"trial","name":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","route":"/trials/nct04722978/"},{"id":"nct06165900","kind":"trial","name":"Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC","route":"/trials/nct06165900/"},{"id":"nct05078047","kind":"trial","name":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","route":"/trials/nct05078047/"},{"id":"nct05909332","kind":"trial","name":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","route":"/trials/nct05909332/"},{"id":"nct06202313","kind":"trial","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06202313/"},{"id":"nct05447702","kind":"trial","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05447702/"},{"id":"nct06313463","kind":"trial","name":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","route":"/trials/nct06313463/"},{"id":"nct07011654","kind":"trial","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","route":"/trials/nct07011654/"},{"id":"nct07638852","kind":"trial","name":"Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.","route":"/trials/nct07638852/"},{"id":"swog-s1418","kind":"trial","name":"SWOG S1418 / NRG BR006","route":"/trials/swog-s1418/"},{"id":"nct02641847","kind":"trial","name":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","route":"/trials/nct02641847/"},{"id":"nct07786428","kind":"trial","name":"Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC","route":"/trials/nct07786428/"},{"id":"nct06434064","kind":"trial","name":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","route":"/trials/nct06434064/"},{"id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05128734/"},{"id":"nct03606967","kind":"trial","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03606967/"},{"id":"nct07151586","kind":"trial","name":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo","route":"/trials/nct07151586/"},{"id":"nct06851299","kind":"trial","name":"The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast","route":"/trials/nct06851299/"},{"id":"nct06140576","kind":"trial","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","route":"/trials/nct06140576/"},{"id":"nct06125080","kind":"trial","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","route":"/trials/nct06125080/"},{"id":"nct06735131","kind":"trial","name":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","route":"/trials/nct06735131/"},{"id":"nct05550415","kind":"trial","name":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","route":"/trials/nct05550415/"},{"id":"nct05862610","kind":"trial","name":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","route":"/trials/nct05862610/"},{"id":"nct06532812","kind":"trial","name":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","route":"/trials/nct06532812/"},{"id":"nct07074106","kind":"trial","name":"TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC","route":"/trials/nct07074106/"},{"id":"nct06538896","kind":"trial","name":"Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu","route":"/trials/nct06538896/"},{"id":"nct07681297","kind":"trial","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","route":"/trials/nct07681297/"},{"id":"nct04301739","kind":"trial","name":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu","route":"/trials/nct04301739/"},{"id":"nct05846789","kind":"trial","name":"Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers","route":"/trials/nct05846789/"},{"id":"nct07256964","kind":"trial","name":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","route":"/trials/nct07256964/"},{"id":"nct05451784","kind":"trial","name":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","route":"/trials/nct05451784/"},{"id":"nct04137653","kind":"trial","name":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","route":"/trials/nct04137653/"},{"id":"nct07271992","kind":"trial","name":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","route":"/trials/nct07271992/"},{"id":"nct06371807","kind":"trial","name":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","route":"/trials/nct06371807/"},{"id":"nct07064018","kind":"trial","name":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","route":"/trials/nct07064018/"},{"id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","route":"/trials/nct06291064/"},{"id":"nct07104266","kind":"trial","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","route":"/trials/nct07104266/"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/"},{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/"},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/"},{"id":"nct06385990","kind":"trial","name":"Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy","route":"/trials/nct06385990/"}]}}